scholarly journals HPV Catch-up Vaccination is Effective but Cervical Screening Should Continue

2021 ◽  
Vol 5 (2) ◽  
pp. 51-53
Author(s):  
Nick F. Hallam
Keyword(s):  
High Risk ◽  
Cervical Screening ◽  
Hpv Vaccination ◽  
Herd Immunity ◽  
High Grade ◽  
Human Papillomavirus Vaccination ◽  
Hpv 16 ◽  
Bivalent Vaccine ◽  
Cervical Disease ◽  
Catch Up

This short communication reports additional research that extends the previously published article - Commentary: HPV Catch-Up Vaccination Reduces the Prevalence of HPV 16 and 18 Infections and Cervical Disease: A Retrospective Study.1 One limitation of that study was uncertainty as to whether the catch-up cohort had actually received HPV (human papillomavirus) vaccination. That information has now been obtained. 87 (59%) of the 147 patients in the catch-up cohort had received at least one dose of HPV bivalent vaccine. 69 of these (representing 79% of those vaccinated) had received three doses (as recommended at the time). Both the vaccinated and unvaccinated subsets of the catch-up cohort show a significant reduction in the prevalence of HPV 16 and/or 18 (with/without other high-risk types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) and of high grade cervical disease compared to an earlier unvaccinated cohort. These results confirm the efficacy of HPV catch-up vaccination and the existence of herd immunity following the introduction of national HPV vaccination campaigns. However, 34 patients (23%) in the catch-up cohort had high grade disease (cervical intraepithelial neoplasia [CIN] 2 or worse), 16 of whom had been vaccinated (12 with three doses, one with two doses and three with one dose of HPV bivalent vaccine) and four of those vaccinated had HPV 16 and/or 18 (with/without other high-risk types), the rest had other HPV high risk types. This emphasises the importance of maintaining cervical screening alongside HPV vaccination.

scholarly journals Acceptability and feasibility of human papillomavirus vaccination for adolescents in school environments in Libreville

2020 ◽  
Vol 9 (9) ◽  
pp. 3541
Author(s):  
Nathalie L. Ambounda ◽  
Sylvain H. Woromogo ◽  
Olive M. Kenmogne ◽  
Felicite E. Yagata Moussa ◽  
Vicky N. Simo Tekem ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
High Risk ◽  
Precancerous Lesions ◽  
Hpv Vaccination ◽  
Immunization Coverage ◽  
Human Papillomaviruses ◽  
Professional Status ◽  
Human Papillomavirus Vaccination ◽  
Cross Sectional

Background: High-risk oncogenic human papillomaviruses (HPV) are the cause of sexually transmitted viral infection. Its persistence is a risk factor for precancerous lesions of the cervix, which will constitute the base of cervical cancer. In the world, the prevalence of high-risk oncogenic HPV is 66.7%, which is higher among women starting their sexual activity.Methods: An analytical cross-sectional study was conducted in high schools in Gabon regarding parents. The variables selected were the socio-cultural and demographic characteristics of the parents, their knowledge of human papillomavirus vaccination and their acceptability of HPV vaccination and finally the feasibility of HPV vaccination. The statistical test used was Pearson's Chi-square, and a difference was considered significant for p<0.05.Results: The majority of parents, 89%, were informed of the existence of cervical cancer. However, 73.4% of them were unaware of the existence of vaccination against cervical cancer. Only 2.4% of parents had vaccinated their daughters against cervical cancer at the time of the study. These parents only 53.4% expressed an interest in vaccinating their daughters in 53.4% of cases. The ability to vaccinate children is associated with the socio-professional status of parents (p˂0.000).Conclusions: The majority of parents approved school-based vaccination against human papillomavirus infections despite its reported cost and lack of information. The integration of anti-HPV vaccination into the expanded programme on immunization in Gabon will improve immunization coverage.

HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination

Vaccine ◽  
2020 ◽  
Vol 38 (40) ◽  
pp. 6304-6311
Author(s):  
Alyssa M. Cornall ◽  
Marion Saville ◽  
Jan Pyman ◽  
Emma T. Callegari ◽  
Fiona H. Tan ◽  
...  
Keyword(s):  
Hpv Vaccination ◽  
High Grade ◽  
Cervical Lesions ◽  
Australian Population ◽  
Catch Up

A brief history of economic evaluation for human papillomavirus vaccination policy

Sexual Health ◽  
2010 ◽  
Vol 7 (3) ◽  
pp. 352 ◽  
Author(s):  
Philippe Beutels ◽  
Mark Jit
Keyword(s):  
Human Papillomavirus ◽  
Economic Evaluation ◽  
Policy Making ◽  
Cervical Screening ◽  
Hpv Vaccination ◽  
Health Economic Evaluation ◽  
Developed Countries ◽  
Economic Evaluations ◽  
Human Papillomavirus Vaccination ◽  
Screening Programs

Background: This commentary discusses key issues for health economic evaluation and modelling, applied to human papillomavirus (HPV) vaccine programs. Methods: We outline some of the specific features of HPV disease and vaccination, and associated policy questions in light of a literature search for economic evaluations on HPV vaccination. Results: We observe that some policy questions could not be reliably addressed by many of the 43 published economic evaluations we found. Despite this, policy making on universal HPV vaccination followed shortly after vaccine licensure in many developed countries, so the role economic evaluation played in informing these decisions (pre-dating 2008) seems to have been fairly limited. For more recent decisions, however, economic evaluation is likely to have been used more widely and more intensively. Conclusions: We expect future cost-effectiveness analyses to be more instrumental in policy making regarding vaccines covering more HPV types, therapeutic HPV vaccines, and novel diagnostic tests for biomarkers of HPV infection and disease integrated with cervical screening programs.

scholarly journals High-Throughput Genotyping of Oncogenic Human Papilloma Viruses with MALDI-TOF Mass Spectrometry

2008 ◽  
Vol 54 (1) ◽  
pp. 86-92 ◽  
Author(s):  
Anna Söderlund-Strand ◽  
Joakim Dillner ◽  
Joyce Carlson
Keyword(s):  
High Throughput ◽  
Cervical Screening ◽  
Blot Hybridization ◽  
Hpv Vaccination ◽  
Intraepithelial Neoplasia ◽  
Comparison Method ◽  
Dot Blot ◽  
Vaccination Programs ◽  
Screening Programs ◽  
Cervical Disease

Abstract Background: Human papilloma virus (HPV) is the major cause of cervical cancer. Use of HPV genotyping in cervical screening programs and for monitoring the effectiveness of HPV vaccination programs requires access to economical, high-throughput technology. Methods: We used the Sequenom MassARRAY platform to develop a high-throughput mass spectrometric (MS) method for detecting 14 specific oncogenic HPV genotypes in multiplex PCR products. We compared results from 532 cervical cell samples to the comparison method, reverse dot blot hybridization (RDBH). Results: The MS method detected all samples found positive by RDBH. In addition, the MS method identified 5 cases of cervical disease (cervical intraepithelial neoplasia of grade I or higher) that RDBH analysis had missed. Discrepancies in specific genotypes were noted in 20 samples, all positive by MS, with an overall concordance of κ = 0.945. Conclusions: The MS high-throughput method, with a processing capacity of 10 × 384 samples within 2 working days and at a consumables cost of about US$2 per sample, performed as well as or better than the comparison method.

scholarly journals Real-world effectiveness of Human Papillomavirus vaccination against vulvovaginal high-grade precancerous lesions and cancers

2020 ◽  
Author(s):  
Christian Dehlendorff ◽  
Louise Baandrup ◽  
Susanne K Kjaer
Keyword(s):  
Human Papillomavirus ◽  
Real World ◽  
Cumulative Incidence ◽  
Precancerous Lesions ◽  
Hpv Vaccination ◽  
Hazard Rates ◽  
High Grade ◽  
Real World Data ◽  
Human Papillomavirus Vaccination ◽  
World Data

Abstract Background Vaccination against human papillomavirus (HPV) has proven to be effective against severe cervical lesions and genital warts, whereas no previous study has provided real-world data on the HPV vaccine effectiveness against high-grade vulvovaginal lesions. Methods A cohort of all women aged 17–26 years, living in Denmark during 2006–2019 was followed in nationwide registers for individual-level information about HPV vaccination and first diagnoses of vulvar and vaginal high-grade intraepithelial lesions or worse (HSIL+). The cumulative incidence of vulvar and vaginal HSIL+, respectively, was estimated with the Aalen-Johansen estimator and Cox proportional hazards regression was used to estimate hazard ratios (HRs) for vulvar and vaginal lesions separately comparing women vaccinated at age &lt;16 years and at age 17–26 years with unvaccinated women. Results The cohort consisted of 514,537 women, of which 50.6% were vaccinated at baseline (&lt;16 years), 31.8% were vaccinated during follow-up (17–26 years) and 17.6% remained unvaccinated. The cumulative incidence was less than 0.6‰ for vulvar HSIL+ and less than 0.2‰ for vaginal HSIL+. Adjusted analyses showed reduced hazard rates for both vulvar (HR = 0.22, 95% CI = 0.13 to 0.38) and vaginal HSIL + (HR = 0.16, 95% CI = 0.04 to 0.55) for women vaccinated at age ≤16 years compared to unvaccinated women. For women vaccinated at 17–26 years, the reductions in hazard rates were smaller for vaginal HSIL+ and close to zero for vulvar HSIL+. Conclusion HPV vaccination before 17 years of age reduces the risk of vulvar and vaginal HSIL+ based on real-world data.

Potential coverage of circulating HPV types by current and developing vaccines in a group of women in Bosnia and Herzegovina with abnormal Pap smears

2015 ◽  
Vol 143 (12) ◽  
pp. 2604-2612
Author(s):  
I. SALIMOVIĆ-BEŠIĆ ◽  
M. HUKIĆ
Keyword(s):  
High Risk ◽  
Bosnia And Herzegovina ◽  
Pap Smear ◽  
Multiple Infections ◽  
Pap Smears ◽  
Abnormal Cytology ◽  
Hpv 16 ◽  
Hpv Dna ◽  
Cervical Disease ◽  
Hpv 18

SUMMARYThe objectives of this study were to identify human papillomavirus (HPV) genotypes in a group of Bosnian-Herzegovinian women with abnormal cytology and to assess their potential coverage by vaccines. HPVs were identified by multiplex real-time PCR test (HPV High Risk Typing Real-TM; Sacace Biotechnologies, Italy) of 105 women with an abnormal cervical Pap smear and positive high-risk (HR) HPV DNA screening test. The most common genotypes in the study were HPV-16 (32·6%, 48/147), HPV-31 (14·3%, 21/147), HPV-51 (9·5%, 14/147) and HPV-18 (7·5%, 11/147). The overall frequency of HR HPV-16 and/or HPV-18, covered by currently available vaccines [Gardasil® (Merck & Co., USA) and Cervarix®; (GlaxoSmithKline, UK)] was lower than the overall frequency of other HPVs detected in the study (40·1%, 59/174,P= 0·017). Group prevalence of HR HPVs targeted by a nine-valent vaccine in development (code-named V503) was higher than total frequency of other HPVs detected (68·0%, 100/147,P< 0·001). Development of cervical cytological abnormalities was independent of the presence of multiple infections (χ2= 0·598,P= 0·741). Compared to other HPVs, dependence of cervical diagnosis and HPV-16, -18 (P= 0·008) and HPV-16, -18, -31 (P= 0·008) infections were observed. Vaccines targeting HR HPV-16, -18 and -31 might be an important tool in the prevention of cervical disease in Bosnia and Herzegovina.

Opportunities to increase rates of human papillomavirus vaccination in the New South Wales school program through enhanced catch-up

Sexual Health ◽  
2016 ◽  
Vol 13 (6) ◽  
pp. 536 ◽  
Author(s):  
Christine Staples ◽  
Michelle Butler ◽  
Jennifer Nguyen ◽  
David N. Durrheim ◽  
Patrick Cashman ◽  
...  
Keyword(s):  
High School Students ◽  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Vaccine Coverage ◽  
Hpv Vaccination ◽  
Vaccination Program ◽  
Completion Rates ◽  
School Program ◽  
Human Papillomavirus Vaccination ◽  
Catch Up

Background The National Human Papillomavirus (HPV) Vaccination Program provides HPV vaccine to high school students through school-based vaccination. We aimed to: 1) assess the vaccine completion rates achieved when general practice is used for completing doses missed at school; 2) estimate the extent of under-notification by general practices of vaccine doses administered; and 3) assess the reasons reported by parents of students for non-completion of HPV vaccination. Methods: A postal survey was conducted of parents and carers of students and identified, using school-program records, as incompletely vaccinated in a large regional area of northern NSW vaccinated during 2010. Information about additional HPV vaccine doses received or reasons for non-completion were sought. Responses were analysed and records cross-checked against the National HPV Vaccination Program Register. Results: Of 660 parents or carers contacted, 207 (31.4%) responded. We found: 1) completion rates increased, an additional 122/207 (45.2%) students had completed all three doses of HPV through their general practitioner (GP); 2) under-notification of GP doses to the National HPV Vaccination Program Register was an issue with only 5/165 (3.0%) reported; 3) the main reason for non-completion was being unaware of the opportunity to catch-up at a GP. Conclusions: Underreporting by GPs of HPV vaccine doses administered and failure to complete courses identifies two opportunities to increase HPV vaccine coverage. These could be addressed by extending provision of catch-up HPV doses in school and by developing practice software solutions for automatic notification of doses from GPs. Reasons given by parents for non-completion, mostly logistical barriers, indicate a high degree of acceptance of HPV vaccination.

Sign in / Sign up

Export Citation Format

Share Document